Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor
– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congressdescribe mechanistic insights for greater potency with verekitug compared to tezepelumab –
– Supports potentially differentiated profile of verekitug across a broad range of inflammatory diseases, including severe asthma, chronic obstructive pulmonary disease (COPD) and chronic rhinosinusitis with nasal polyps (CRSwNP) –
WALTHAM, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the presentation of translational pharmacology modeling data supporting verekitug's Thymic Stromal Lymphopoietin (TSLP) receptor targeting as a mechanism for greater potency when compared to treatments targeting the TSLP ligand. Data were presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress taking place June 13-16, 2025, in Glasgow, United Kingdom.
TSLP is a cytokine that is a key driver of the inflammatory response in major allergic and inflammatory diseases, such as asthma, where disruption of TSLP signaling has been clinically validated as an effective treatment approach. Because TSLP is a target upstream in the inflammatory cascade, blocking the TSLP receptor presents an opportunity for a single treatment to impact the drivers of multiple pathological inflammatory processes across a broad set of diseases. Upstream is developing verekitug in multiple severe respiratory diseases including severe asthma, COPD, and CRSwNP. Verekitug is the only monoclonal antibody currently in clinical development that targets and inhibits the TSLP receptor.
'These data reinforce our belief in the differentiated profile of verekitug, as the model elucidates important biologic parameters that drive the differentiated rapid, substantial and sustained treatment effects observed through TSLP receptor inhibition with verekitug,' said Aaron Deykin, MD, Chief Medical Officer and Head of Research & Development of Upstream Bio. 'We look forward to further assessing the potential translation of this unique mechanism into clinical benefit in patients with severe respiratory diseases, first with top-line Phase 2 clinical data in CRSwNP in the third quarter of this year followed by data in severe asthma in the first half of 2026.'
Data presented used an in silico system pharmacology modeling approach to provide a mechanism-based understanding for the observed potency of verekitug and are summarized as follows:
A digital version of the presentation can be found on the Upstream Bio website.
About TSLP and TSLPR Blockade
Thymic Stromal Lymphopoietin (TSLP) is a cytokine that is a key driver of the inflammatory response in major allergic and inflammatory diseases, such as asthma, where disruption of TSLP signaling has been clinically validated as an effective therapeutic strategy.
TSLP activation is one of the first events in the inflammatory cascade stimulated by allergens, viruses and other triggers, initiating the activation of downstream targets such as IL-4, IL-5, IL-13, IL-17 and IgE. Because TSLP is a target upstream in the inflammatory cascade, blocking the TSLP receptor (TSLPR) presents an opportunity for a single treatment to impact the drivers of multiple pathological inflammatory processes across a broad set of diseases.
About Verekitug
Verekitug is a novel recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to the TSLP receptor and inhibits proinflammatory signaling initiated by TSLP. It is the only monoclonal antibody currently in clinical development that targets and inhibits the TSLP receptor. Verekitug is currently being evaluated in two separate multi-national, placebo-controlled, randomized Phase 2 clinical trials, the VALIANT trial in patients with severe asthma (NCT06196879) and the VIBRANT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) (NCT06164704). Upstream Bio is also initiating a Phase 2 clinical trial (NCT06981078) of verekitug in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
In preclinical studies, verekitug demonstrated high occupancy of the TSLP receptor and potent inhibition of TSLP signaling. Additionally, verekitug inhibited cytokine production from both CD4+ T cells and ILC2 cells and completely suppressed skin allergic reactions in a non-human primate model, suggesting that it may be effective against multiple types of inflammation.
Three clinical trials have been completed for verekitug, including a Phase 1 single-ascending dose (SAD) clinical trial and a Phase 1b multiple-ascending dose (MAD) clinical trial. In these trials, verekitug was well tolerated, had no clinically meaningful immunogenicity, and showed a predictable and consistent pharmacokinetic profile and high subcutaneous bioavailability.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and is initiating development in chronic obstructive pulmonary disease. Upstream Bio's team is committed to maximizing verekitug's unique attributes to address the substantial unmet needs for patients underserved by today's standard of care. To learn more, please visit www.upstreambio.com.
Forward-Looking Statements
This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'continue,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'predict,' 'project,' 'seeks,' 'should,' 'target,' 'will' and variations of these words or similar expressions. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, express or implied statements regarding: the clinical development of verekitug for the treatment of severe asthma, CRSwNP and COPD, including the initiation, timing, progress and results of ongoing and planned clinical trials; expectations for future discussions with regulatory authorities and the potential of the endpoints of the Company's clinical trials to produce data that could support submissions for product approval; expectations regarding the differentiation, safety, efficacy or tolerability of verekitug; expectations regarding the translation of pharmacology modeling data of verekitug to clinical effects; and assessments comparing non-head-to-head clinical data of verekitug to published data for tezepelumab. Any forward-looking statements in this press release are based on the Company's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Readers are cautioned that actual results, levels of activity, safety, efficacy, performance or events and circumstances could differ materially from those expressed or implied in the Company's forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to: Upstream Bio's ability to advance verekitug through clinical development, and to obtain regulatory approval of and ultimately commercialize verekitug on the expected timeline, if at all; the initiation, timing, progress and results of clinical trials; Upstream Bio's ability to fund its development activities and achieve development goals; Upstream Bio's dependence on third parties to conduct clinical trials and manufacture verekitug, and commercialize verekitug, if approved; Upstream Bio's ability to attract, hire and retain key personnel, and protect its intellectual property; Upstream Bio's financial condition and need for substantial additional funds in order to complete development activities and commercialize verekitug, if approved; regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; Upstream Bio's competitors and industry; and other risks and uncertainties described in greater detail under the caption 'Risk Factors' in Upstream Bio's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the SEC. Any forward-looking statements represent Upstream Bio's views only as of today and should not be relied upon as representing its views as of any subsequent date. Upstream Bio explicitly disclaims any obligation or undertaking to update any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based except to the extent required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Investor and Media Contact: Meggan Buckwell Director, Corporate Communications and Investor Relations [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
an hour ago
- Fox News
Experimental cholesterol pill cuts heart attack risk with 'convenient' once-daily dose
A new daily pill could provide an easier, more convenient way to lower cholesterol and reduce heart attack and stroke risk. The experimental medication, called Obicetrapib, underwent a Phase 3 clinical trial at Monash University in Australia. The trial included more than 2,500 people averaging 65 years of age. All had either been diagnosed with heart disease or had genetically high cholesterol, according to a university press release. All participants were receiving "maximum tolerated doses" of cholesterol-lowering therapy. One group received Obicetrapib and another group took a placebo, while still maintaining their existing cholesterol drugs. After 12 weeks, the participants taking the new drug showed a 32.6% reduction in LDL cholesterol and a 33.5% drop in lipoprotein(a) [Lp(a)], the release stated. The findings were presented last month at the European Atherosclerosis Society Congress in the U.K. and were also published in The New England Journal of Medicine. "We know that many people at high risk of heart attack or stroke don't get their cholesterol levels low enough, even on the best available treatments," said study lead Professor Stephen Nicholls, director of Monash University's Victorian Heart Institute and Monash Health's Victorian Heart Hospital, in the release. "We know that many people at high risk of heart attack or stroke don't get their cholesterol levels low enough, even on the best available treatments." "Obicetrapib offers a promising new option — not only did it lower LDL cholesterol by over 30%, but we also saw a reduction in Lp(a), which is much harder to treat and has been linked to increased heart disease risk." Low-density lipoprotein (LDL), which is sometimes called "bad cholesterol," is associated with negative health effects when present in high amounts. LDL can build up in the blood vessels and increase heart attack and stroke risk, the researchers cautioned. Lipoprotein(a), or Lp(a), is a protein that is known to greatly increase the chances of a heart attack when it's present in high levels in the blood. Unlike LDL, Lp(a) is an inherited risk factor that can't be modified with healthy behaviors or medications. Obicetrapib was found to be "well-tolerated" by the participants, the researchers noted. "This could be a valuable tool in the fight against heart disease," Nicholls added. "It's convenient, it's effective, and it may help close the gap for patients who've run out of options." The study — which was funded by NewAmsterdam Pharma, a developer of Obicetrapib that is based in the Netherlands — did have some limitations, the researchers noted. For example, the participants were not chosen based on high Lp(a), which means the study did not determine how the drug impacted those with elevated levels of the protein. Additionally, the study assessed changes in LDL levels, but did not measure actual heart attack or stroke outcomes. For more Health articles, visit More studies are needed to follow patients for longer time periods and to include more diverse cohorts, the researchers acknowledged. Fox News Digital reached out to the researchers for additional comment.
Yahoo
an hour ago
- Yahoo
The CEO of British telecom giant BT warns AI could lead to further job cuts at the firm
The CEO of British telecom giant BT has warned that AI may lead to further cuts at the firm. BT announced plans in 2023 to cut up to 55,000 jobs by 2030. CEO Allison Kirkby told the FT that such proposals "did not reflect the full potential of AI." Executives warning of the potential impact of artificial intelligence on white-collar jobs is becoming an increasingly familiar tale. The latest is Allison Kirkby, the CEO of British telecommunications giant BT. In an interview with the Financial Times published Sunday, Kirkby said that advancements in AI technology could lead to further cuts at the firm. BT announced in 2023 plans to cut up to 55,000 jobs by 2030 as part of a push to reduce its cost base by the end of the decade. But Kirkby told the FT that this plan "did not reflect" AI's "full potential." "Depending on what we learn from AI ... there may be an opportunity for BT to be even smaller by the end of the decade," she said. BT has turned to AI in recent years to reinvent processes in areas like customer service. The company announced in 2024 that it was using generative AI to aid sales and support operations across BT and EE, its mobile network division. In December, the firm said that EE's virtual assistant, dubbed "Aimee," was handling up to 60,000 customer conversations a week. BT is not alone in its attempts to automate such tasks. Swedish payments company Klarna has been open about its efforts to use AI to run its customer service desks. In 2024, Klarna said its OpenAI-powered AI assistant was carrying out the work of 700 full-time customer service agents. The firm's CEO, Sebastian Siemiatkowski, has been a strong advocate of AI but has since softened his position on the tech, saying in May that certain cost-cutting efforts had gone too far and that Klarna was now recruiting for its customer service operation, Bloomberg reported. But Siemiatkowski has remained confident that AI poses a major threat to white-collar jobs going forward. Speaking on The Times Tech podcast earlier this month, Siemiatkowski said that the technology had played a major role in "efficiency gains" at Klarna and that its workforce had reduced from about 5,500 to 3,000 people in the last two years as a result. "My suspicion again is that there will be an implication for white-collar jobs, and when that happens, that usually leads to at least a recession in the short term," he added. "Unfortunately, I don't see how we could avoid that, with what's happening from a technology perspective." AI companies themselves have sounded the alarm that their product could significantly impact the job market. Anthropic CEO Dario Amodei recently warned that AI could eliminate half of all entry-level white-collar jobs within the next five years. "We, as the producers of this technology, have a duty and an obligation to be honest about what is coming," Amodei told Axios in May. "I don't think this is on people's radar. Read the original article on Business Insider
Yahoo
an hour ago
- Yahoo
Renault boss Luca de Meo to step down, company says
The head of French carmarker Renault, Luca de Meo, is to quit "to take on new challenges outside the automobile sector", the company said on Sunday. "After five years leading Renault Group, Luca de Meo has announced his decision to leave his position," said a company statement, adding that his departure would take effect on July 15. According to Le Figaro newspaper, de Meo will become the new chief executive of French luxury group Kering, owner of Gucci, Yves Saint-Laurent, Balenciaga and other premium brands. Kering's current chief executive is Francois-Henri Pinault, son of the group's billionaire founder Francois Pinault. Francois-Henri Pinault has announced a management shake-up that would see him stay on as chairman of the group. Kering has been struggled to turn things around at Gucci, its flagship brand, which accounts for half of its overall sales. Gucci sales fell by 23 percent last year, contributing to a sharp plunge in net profits to 1.13 billion euros ($1.3 billion) for the group. The bad results for Gucci continued into the first quarter of this year, with another 24-percent sales slump compared to the same period last year. Contacted by AFP, Kering declined to comment on reports that it had recruited de Meo. As head of Renault, de Meo has been key to the carmaker's partnership with Japan's financially troubled Nissan, which has been under tension over the past couple of years. Renault and Nissan said at the end of March they had revised their partnership to allow for a reduction in their cross-shareholdings from 15 percent to 10 percent, and other measures. The two carmakers have been partners since 1999 when Renault rescued Nissan from bankruptcy. But numerous tensions emerged, particularly over Renault's greater holding in Nissan, and in 2023 the carmakers worked to rebalance their alliance. Nissan announced last year thousands of job cuts after reporting a 93 percent plunge in first-half net profit, and it expects to post a loss of over $500 million for 2024. Renault said last month it expected to book a 2.2-billion-euro hit in the first quarter due to Nissan's turnaround plan. alb/rmb/jj Sign in to access your portfolio
